Advertisement
Screener

Revolution Medicines, Inc. (RVMD) Increase (Decrease) in Prepaid Expense and Other Assets

2.8 / 5 stars · 68/120 Roast Me

Revolution Medicines, Inc. Increase (Decrease) in Prepaid Expense and Other Assets

Revolution Medicines, Inc. (RVMD) reported Increase (Decrease) in Prepaid Expense and Other Assets of $41.01 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.

Financial Statements › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-05

  • Revolution Medicines, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was $30.54M, a 314.89% increase year-over-year.
  • Revolution Medicines, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was $10.47M.
  • Revolution Medicines, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was $3.38M, a 33.94% decline year-over-year.
  • Revolution Medicines, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was $5.36M.
  • Revolution Medicines, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2025 was $9.67M, a 0.32% decline from fiscal 2024.
  • Revolution Medicines, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2024 was $9.70M, a 266.52% increase from fiscal 2023.
  • Revolution Medicines, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2023 was $2.65M, a 29.98% decline from fiscal 2022.
  • Revolution Medicines, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2022 was $3.78M.
Period endIncrease (Decrease) in Prepaid Expense and Other Assets 3 monthIncrease (Decrease) in Prepaid Expense and Other Assets 6 monthIncrease (Decrease) in Prepaid Expense and Other Assets 9 monthIncrease (Decrease) in Prepaid Expense and Other Assets 12 month
2026-06-30$30.54M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05
$41.01M
10-Q · filed 2026-08-05
$44.39M
derived: sum of 3 quarters · filed 2026-08-05
$49.74M
derived: sum of 4 quarters · filed 2026-08-05
2026-03-31$10.47M
10-Q · filed 2026-05-06
$13.85M
derived: sum of 2 quarters · filed 2026-05-06
$19.20M
derived: sum of 3 quarters · filed 2026-05-06
$26.56M
derived: sum of 4 quarters · filed 2026-08-05
2025-12-31$3.38M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25
$8.73M
derived: sum of 2 quarters · filed 2026-02-25
$16.09M
derived: sum of 3 quarters · filed 2026-08-05
$9.67M
10-K · filed 2026-02-25
2025-09-30$5.36M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05
$12.72M
derived: sum of 2 quarters · filed 2026-08-05
$6.29M
10-Q · filed 2025-11-05
$11.40M
derived: sum of 4 quarters · filed 2026-08-05
2025-06-30$7.36M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05
$935.00K
10-Q · filed 2026-08-05
$6.05M
derived: sum of 3 quarters · filed 2026-08-05
$1.69M
derived: sum of 4 quarters · filed 2026-08-05
2025-03-31-$6.43M
10-Q · filed 2026-05-06
-$1.31M
derived: sum of 2 quarters · filed 2026-05-06
-$5.67M
derived: sum of 3 quarters · filed 2026-05-06
$2.68M
derived: sum of 4 quarters · filed 2026-05-06
2024-12-31$5.11M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25
$755.00K
derived: sum of 2 quarters · filed 2026-02-25
$9.11M
derived: sum of 3 quarters · filed 2026-02-25
$9.70M
10-K · filed 2026-02-25
2024-09-30-$4.36M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05
$4.00M
derived: sum of 2 quarters · filed 2025-11-05
$4.59M
10-Q · filed 2025-11-05
$6.84M
derived: sum of 4 quarters · filed 2026-02-25
2024-06-30$8.35M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06
$8.94M
10-Q · filed 2025-08-06
$11.20M
derived: sum of 3 quarters · filed 2026-02-25
$12.06M
derived: sum of 4 quarters · filed 2026-02-25
2024-03-31$590.00K
10-Q · filed 2025-05-07
$2.84M
derived: sum of 2 quarters · filed 2026-02-25
$3.71M
derived: sum of 3 quarters · filed 2026-02-25
$4.85M
derived: sum of 4 quarters · filed 2026-02-25
2023-12-31$2.25M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25
$3.12M
derived: sum of 2 quarters · filed 2026-02-25
$4.26M
derived: sum of 3 quarters · filed 2026-02-25
$2.65M
10-K · filed 2026-02-25
2023-09-30$870.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06
$2.00M
derived: sum of 2 quarters · filed 2024-11-06
$394.00K
10-Q · filed 2024-11-06
-$4.19M
derived: sum of 4 quarters · filed 2025-02-26
2023-06-30$1.14M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07
-$476.00K
10-Q · filed 2024-08-07
-$5.06M
derived: sum of 3 quarters · filed 2025-02-26
-$5.90M
derived: sum of 4 quarters · filed 2025-02-26
2023-03-31-$1.61M
10-Q · filed 2024-05-08
-$6.20M
derived: sum of 2 quarters · filed 2025-02-26
-$7.03M
derived: sum of 3 quarters · filed 2025-02-26
-$1.25M
derived: sum of 4 quarters · filed 2025-02-26
2022-12-31-$4.59M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26
-$5.42M
derived: sum of 2 quarters · filed 2025-02-26
$363.00K
derived: sum of 3 quarters · filed 2025-02-26
$3.78M
10-K · filed 2025-02-26
2022-09-30-$834.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06
$4.95M
derived: sum of 2 quarters · filed 2023-11-06
$8.37M
10-Q · filed 2023-11-06
$7.73M
derived: sum of 4 quarters · filed 2024-02-26
2022-06-30$5.78M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08
$9.20M
10-Q · filed 2023-08-08
$8.56M
derived: sum of 3 quarters · filed 2024-02-26
$7.87M
derived: sum of 4 quarters · filed 2024-02-26
2022-03-31$3.42M
10-Q · filed 2023-05-08
$2.78M
derived: sum of 2 quarters · filed 2024-02-26
$2.08M
derived: sum of 3 quarters · filed 2024-02-26
$1.96M
derived: sum of 4 quarters · filed 2024-02-26
2021-12-31-$638.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26
-$1.33M
derived: sum of 2 quarters · filed 2024-02-26
-$1.46M
derived: sum of 3 quarters · filed 2024-02-26
-$198.00K
10-K · filed 2024-02-26
2021-09-30-$694.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07
-$817.00K
derived: sum of 2 quarters · filed 2022-11-07
$440.00K
10-Q · filed 2022-11-07
$282.00K
derived: sum of 4 quarters · filed 2023-02-27
2021-06-30-$123.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09
$1.13M
10-Q · filed 2022-08-09
$976.00K
derived: sum of 3 quarters · filed 2023-02-27
$517.00K
derived: sum of 4 quarters · filed 2023-02-27
2021-03-31$1.26M
10-Q · filed 2022-05-09
$1.10M
derived: sum of 2 quarters · filed 2023-02-27
$640.00K
derived: sum of 3 quarters · filed 2023-02-27
-$21.00K
derived: sum of 4 quarters · filed 2023-02-27
2020-12-31-$158.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27
-$617.00K
derived: sum of 2 quarters · filed 2023-02-27
-$1.28M
derived: sum of 3 quarters · filed 2023-02-27
$1.92M
10-K · filed 2023-02-27
2020-09-30-$459.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10
-$1.12M
derived: sum of 2 quarters · filed 2021-11-10
$2.08M
10-Q · filed 2021-11-10
$689.00K
derived: sum of 4 quarters · filed 2022-02-28
2020-06-30-$661.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11
$2.54M
10-Q · filed 2021-08-11
$1.15M
derived: sum of 3 quarters · filed 2022-02-28
$3.10M
derived: sum of 4 quarters · filed 2022-02-28
2020-03-31$3.20M
10-Q · filed 2021-05-10
$1.81M
derived: sum of 2 quarters · filed 2022-02-28
$3.77M
derived: sum of 3 quarters · filed 2022-02-28
$3.71M
derived: sum of 4 quarters · filed 2022-02-28
2019-12-31-$1.39M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28
$563.00K
derived: sum of 2 quarters · filed 2022-02-28
$512.00K
derived: sum of 3 quarters · filed 2022-02-28
$541.00K
10-K · filed 2022-02-28
2019-09-30$1.96M
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12
$1.91M
derived: sum of 2 quarters · filed 2020-11-12
$1.93M
10-Q · filed 2020-11-12
2019-06-30-$51.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10
-$22.00K
10-Q · filed 2020-08-10
2019-03-31$29.00K
10-Q · filed 2020-05-14
2018-12-31$909.00K
10-K · filed 2021-03-02

Similar stocks

Stock NameCountryMarket CapPE Ratio
BIOGEN INC. (BIIB)United States$33.427B19.60
EXELIXIS, INC. (EXEL)United States$14.358B16.15
NEUROCRINE BIOSCIENCES INC (NBIX)United States$14.131B24.25
HALOZYME THERAPEUTICS, INC. (HALO)United States$13.083B21.59
Twist Bioscience Corp (TWST)United States$11.540B-47.21
BIO-TECHNE Corp (TECH)United States$11.379B74.68
REPLIGEN CORP (RGEN)United States$10.755B185.31
Krystal Biotech, Inc. (KRYS)United States$10.210B45.56
Kymera Therapeutics, Inc. (KYMR)United States$9.631B-31.69
ImmunityBio, Inc. (IBRX)United States$9.157B-9.29